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Dry eye syndrome (DES) is a frequent cause of office vis-
its due to ocular discomfort and commonly leads to prob-
lems with sustained visual activities.1 These include
problems during reading, using a computer, driving at night
and carrying out professional work.2–3 DES manifests more
in elderly people.4–6 Moreover, it affects women more
selectively.7
DES is a complex condition involving the lacrimal glands,
eyelids, and tear film, as well as a variety of ocular surface tis-
sues including epithelial, inflammatory, immune, and goblet
cells.8
Essential fatty acids (EFAs) have been of interest in the
area of dry eye disease treatment. Both topical and systemic
EFAs have been evaluated in regard to alleviation of DES
manifestations. In this paper we try to review the literature
in regard to efficacy of using EFAs to treat DES.Source of EFAs
EFAs are fatty acids that humans and other animals must
ingest because the body requires them for good health but
cannot synthesize them.9 These are polyunsaturated fats.10
The EFAs omega-3 and omega-6 play pivotal functions
and display a wide spectrum of positive effects in the body,
such as: helping to lower cholesterol and triglyceride levels;
giving energy to the body; helping to reduce acute and
chronic inflammation; reducing respiratory and asthma-like
symptoms; enhancing appropriate pre- and postnatal devel-
opment mainly of the central and peripheral nervous systems;
helping in the regulation of blood pressure; reducing the
odds of developing cancer, heart disease, and stroke; man-
aging emotional distress and depression; and benefiting
patients with neurodegenerative disorders.11–16
Some of the food sources of omega-3 and omega-6 fatty
acids are fish and shellfish,17,18 flaxseed (linseed, (hemp oil,e:
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sunflower seeds, leafy vegetables and walnuts.10Role of EFAs in the management of DES –
pathogenesis
Many hypothesize that the cause of dry eye is inflamma-
tory. The omega-3 fatty acid eicosapentaenoic acid (EPA)
and the omega-6 fatty acid arachidonic acid (AA) act compet-
itively as substrate for both enzymes cyclooxygenase and 5-
lipoxygenase. The anti-inflammatory action is believed to
result from the synthesis of prostaglandin E3 (PGE3) and of
leukotriene B5 (LTB5(from EPA that inhibits the conversion
of AA to potentially harmful inflammatory mediators prosta-
glandin E2 (PGE2) and leukotriene B4 (LTB4).19Role of systemic EFAs in the management of DES –
clinical trials
Multiple trials looked at the effect of oral supplement of
omega-3 and omega-6 in the treatment of DES. A large cross
sectional study by Miljanovic´ et al.20 has suggested that a
higher dietary intake of omega-3 fatty acids is associated with
a decreased presence of DES in women.
Barabino et al.21 evaluated the effect of linoleic acid and
gammalinolenic acid, on chronic ocular inflammation in 26
patients with aqueous-deficient keratoconjunctivitis sicca.
Statistically significant changes in symptoms (P < 0.005), liss-
amine green staining (P < 0.005), and ocular surface inflam-
mation (P < 0.05) occurred in the study group compared
with controls.
Aragona et al.22 evaluated the effect of oral omega-6
essential fatty acids on PGE(1) tear content and signs and
symptoms of ocular discomfort in patients with Sjögren’s syn-
drome(SS). This was a randomized, double-masked, con-
trolled, clinical trial involving 40 patients with primary SS.
Twenty patients received omega-6 supplements while con-
trols received placebo. In omga-6 treatment group signifi-
cant changes were noted in the following: increased tear
PGE1 levels, reduction of DES symptom score, and improved
corneal fluorescein stain.
Wojtowicz et al.23 investigated the potential effect of die-
tary supplementation with omega-3 fatty acid on lipid com-
position of meibum, aqueous tear evaporation, and tear
volume in patients with dry eye. Thirty-six patients were
included in this case-control trial whom received a daily dose
of fish oil, containing 450 mg of eicosapentaenoic acid,
300 mg of docosahexaenoic acid, and 1000 mg of flaxseed
oil for 90 days. At the end of the study, 70% of the patients
treated with omega-3 supplements became asymptomatic
and Schirmer testing together with fluorophotometry sug-
gested that the omega-3 supplement increased tear secre-
tion. A similar improvement was reported by Kokke et al.24
in 76 patients with contact lens related DES following treat-
ment with omega-6 supplements.
Tear film hyperosmolarity is a focal factor in dry eye. Lar-
mo et al.25 evaluated in a double-blind, randomized, parallel
trial, effect of consumption of 2 g of sea buckthorn (SB) oil,
containing omega-3 and omega-6 fatty acids and anti-oxi-
dants daily for 3 months to improve dry eye symptoms. There
was a general increase in the osmolarity from baseline to the
end of the intervention. Compared with the placebo group,the increase was significantly less in the SB group when all
participants were included (P = 0.04) and when only partici-
pants consuming the study products for at least 80% of the
intervention days were included. This positively affected the
dry eye symptoms.
Some reports tried to evaluate the effect of omega-3 defi-
ciency on severity of DES. Viau et al.26 evaluated whether a
dietary deficiency in omega-3 may increase the severity of
the pathology in a scopolamine-induced model of dry eye
in the rat. Rats of three consecutive generations were bred
under a balanced diet or a diet deprived of omega-3. Dry
eye was experimentally induced by continuous scopolamine
delivery in female animals from the third generation of both
groups. Dryness was evaluated in vivo using fluorescein stain-
ing. Deficiency in omega-3 supplement does not increase the
severity of dry eye in a rat model of dry eye.
Jackson et al.27 evaluate the effect of a prescription-only
medical food supplement containing omega-3 and omega-
6 essential fatty acids on dry eye signs and symptoms, with
or without concomitant topical cyclosporine. A proper bal-
ance of omega-3 and omega-6 essential fatty acids improved
tear break up time and relieved patient symptoms. The addi-
tion of topical cyclosporine did not show any extra benefit.
Role of systemic EFAs in the reducing inflammation of
DES – clinical trials
Pinazo-Durán et al.28 in a prospective case control study
have evaluated clinical outcomes, and expression levels of
inflammation and immune response mediators in human
reflex tear samples in patients diagnosed with nonsevere
DEDs whom received a combination of antioxidants and
omega-3 essential fatty acids for three months. Levels of
interleukin (IL)-1b, IL6, and IL10 in tears were significantly
lower in the treatment versus control group. Subjective
symptoms of dry eye significantly improved in the treatment
group.
Brignole-Baudouin et al.29 in a multicentre, double-
masked, randomized, controlled trial demonstrated that sup-
plementation with omega-3 and omega-6 fatty acids can
reduce expression of HLA-DR conjunctival inflammatory mar-
ker and may help improve DES symptoms.
Role of topical EFAs in the management of DES –
clinical trials
Rashid et al.30 used topical drops of ALA and linoleic acid
EFAs in different formulations in a mouse model in which dry
eye was both pharmacologically and environmentally induced.
Treatment with ALA significantly decreased corneal fluo-
rescein staining compared with both vehicle and untreated
controls. Additionally, ALA treatment was associated with a
significant decrease in CD11b+ cell number, expression of
corneal Interleukin-1a and Tumor necrosis factor (TNF) and
conjunctival TNF. All these are important inflammatory medi-
ators that are raised in DES patients.Conclusion
A clear answer exists to our concern: ‘‘Essential Fatty
Acids in the treatment of Dry Eye Syndrome: A myth or real-
ity?’’, as most of the studies suggest a beneficial role of
Essential fatty acids in the treatment of dry eye syndrome 197omega-3 and omega-6 supplement in reducing inflammation
and improving DES symptoms. We therefore find it a reason-
able practice to encourage higher consumption of foods rich
with those EFAs initially followed by prescribing oral supple-
ments in patients not satisfied with topical medications alone.
Although it should be kept in mind that these supplements
need some time to work and commitment from patients to
achieve its desired goal. More studies are required in order
to consider these supplements as part of an established pro-
tocol to treat DES.
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